Oxford University’s preliminary coronavirus vaccine is 70.4% effective according to preliminary data from phase 3 studies.
The effectiveness depended on the dosage regimen, the university said in a statement. The vaccine, which was developed with pharmaceutical company AstraZeneca, was 90% effective when given in half a dose and then a full dose, and 62% effective when given in two full doses.
There were no hospitalized or severe cases of the virus among those who received the vaccine, the university said in a statement.
“These results show that we have an effective vaccine that will save many lives. Excitingly, we have found that one of our dosage regimens can be about 90% effective. If this dosage regimen is used, more people could be vaccinated with the proposed vaccine Care, “said Professor Andrew Pollard, the Oxford Vaccine Group’s chief investigator.
After the team announced last week that phase 2 trials in healthy older adults showed the vaccine candidate is safe and elicits an immune response.
The phase 2 study, which involved 560 adults, including 240 over 70 years of age, found that the vaccine caused few side effects and elicited immune responses in both parts of the immune system in all age groups.
The news from Oxford comes after the results showed that the vaccines Pfizer and Moderna developed were 95% effective.
The vaccine, developed by Pfizer and BioNTech, was 94% effective in adults over 65 years of age who are at higher risk of developing serious illness.
Some experts are now saying a vaccine could be available to healthcare workers and those more susceptible to the virus by the end of 2020.
Although the Oxford vaccine appears to be less effective than Pfizer and Moderna’s, it is made from a weakened cold virus that has been genetically modified. It can be stored in a regular refrigerator rather than in ultra-cold temperatures like the Pfizer vaccine.